Trial reportJournal for immunotherapy of cancer2022
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
Open access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.Nature medicine · 2022Trial
- Exploring LTB-mediated T cell differentiation as a prognostic marker in triple-negative breast cancer.Breast cancer research : BCR · 2026Article
- Hybrid bioinspired nanovescicles target tumor endothelial cells and regulate immuno-microenvironment for triple-negative breast cancer therapy.Journal of translational medicine · 2026Article
- B-cells in breast cancer: current insights and challenges.Frontiers in oncology · 2026Review
- Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy.Oncoimmunology · 2025Review
- Recent progress in immune evasion mechanisms of triple-negative breast cancer.Journal of translational medicine · 2025Review
- Cantharidin-Loaded Nanomedicine Modified with Amphiphilic Peptides Induce Immunogenic Cell Death to Enhance PD-1 Blockade.ACS applied materials & interfaces · 2025Article
- Remodeling the tumor microenvironment: regulatory effects of β-sitosterol and luteolin on the immunosuppressive milieu in endometrial carcinoma and implications for combinatorial immunotherapy.Frontiers in immunology · 2025Review
- Review
- Chemotherapy and the Extra-Tumor Immune Microenvironment: EXTRA-TIME.Cancer discovery · 2024Article
- Immunopotentiating effects of herb-partitioned moxibustion on the spleens of cyclophosphamide-induced immunosuppressed rats.Chinese medicine · 2024Article
- Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.Frontiers in immunology · 2024Review
- Improving cancer immunotherapyActa pharmaceutica Sinica. B · 2023Article
- Update on Classic and Novel Approaches in Metastatic Triple-Negative Breast Cancer Treatment: A Comprehensive Review.Biomedicines · 2023Review
- Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab.Journal for immunotherapy of cancer · 2023Article
- Clinical trials of immunotherapy in triple-negative breast cancer.Breast cancer research and treatment · 2022Review
- Chimeric Oncolytic Adenovirus Armed Chemokine Rantes for Treatment of Breast Cancer.Bioengineering (Basel, Switzerland) · 2022Article
- Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer.Cancer research communications · 2022Article
- Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.Therapeutic advances in medical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 6 institutions in 1 country.
Carey K Anders *Duke Cancer Institute, Durham, North Carolina, USA.
Mark G Woodcock *Division of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.ORCID 0000-0001-7348-4980
Amanda E D Van SwearingenDuke Cancer Institute, Durham, North Carolina, USA.ORCID 0000-0002-4287-9741
Dominic T MooreLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Maria J SambadeLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Sonia LaurieLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Alexander RobesonLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Oleg KolupaevLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Luz A CuaboyLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Amy L GarrettLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Karen McKinnonLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Kristen CowensLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Dante BortoneLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Benjamin C CalhounDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Alec D WilkinsonLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Lisa CareyDivision of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Trevor JollyDivision of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Hyman MussDivision of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Katherine Reeder-HayesDivision of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Rebecca KaltmanDepartment of Hematology and Oncology, George Washington Cancer Center, Washington, District of Columbia, USA.
Rachel JankowitzDivision of Hematology/Oncology, University of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Vinay GudenaDivision of Hematology/Oncology, Cone Health Cancer Center, Greensboro, North Carolina, USA.
Oludamilola OlajideRex Hematology Oncology Associates, Rex Cancer Care, Raleigh, North Carolina, USA.
Charles PerouLineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
E Claire DeesDivision of Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Benjamin G Vincent *Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Jonathan S Serody *Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA jonathan_serody@med.unc.edu.
University of North Carolina at Chapel Hill · USDuke Cancer InstituteCone Health · USGeorge Washington University · USRex Hospital · USUniversity of Pittsburgh · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MWomen's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8MTissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN CARLISLE CALHOUN · 1992 to 2026
$59.3MSEEDING POSTDOCTORAL INNOVATORS IN RESEARCH &EDUCATIONK12GM000678 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DONALD T LYSLE, Kathryn Joanna Reissner · 1999 to 2026
$30.9MGvl mHA Specific T Cell Responses Prevent AML Relapse Following Allogeneic Stem Cell Transplantation.R37CA247676 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VINCENT, BENJAMIN G · 2020 to 2025
$3.6MEnhancing Innate Immune Reconstitution Post Allogeneic HSCT.R01HL155098 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jonathan S. Serody · 2021 to 2026
$3.5MDuke-UNC Chapel Hill Immunotherapy Training GrantT32CA211056 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHAO, NELSON J., SERODY, JONATHAN S. · 2017 to 2021
$2.2MNCI NIH HHS P30 CA014236NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA058223NCI NIH HHS R37 CA247676NCI NIH HHS T32 CA211056NHLBI NIH HHS R01 HL155098NIGMS NIH HHS K12 GM000678
Abstract
purposeTriple negative breast cancer (TNBC) is characterized by the presence of immune cells in the tumor microenvironment, however, the response to single-agent immune checkpoint inhibitor (ICI) therapy is modest. Preclinical models have demonstrated that intratumoral regulatory T cells (T PATIENTS AND
methods40 patients with pretreated metastatic TNBC were enrolled. The primary endpoints were progression-free survival (PFS) and change in peripheral blood T
resultsMedian PFS was 1.8 months, and the ORR was 21%. T
conclusionsAmong patients with heavily pretreated TNBC, Cy prior to pembrolizumab did not significantly deplete T
Indexed as
AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideFemaleHumansImmunotherapyMiddle AgedNeoplasm MetastasisTriple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedCyclophosphamidepembrolizumabbreast neoplasmsclinical trialsimmunotherapyphase II as topicprogrammed cell death 1 receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.